Savient rallies in broadly higher drug sector
June 17, 2009 at 11:01 AM EDT
As drug and biotech stocks make broad early gains, shares of Savient Pharmaceuticals stand out, rallying nearly 30% as a Food and Drug Administration advisory panel recommends approval for its drug Krystexxa.
